Author Correction: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.
作者信息
Hashimoto Masashi, Kuroda Shinji, Kanaya Nobuhiko, Kadowaki Daisuke, Yoshida Yusuke, Sakamoto Masaki, Hamada Yuki, Sugimoto Ryoma, Yagi Chiaki, Ohtani Tomoko, Kumon Kento, Kakiuchi Yoshihiko, Yasui Kazuya, Kikuchi Satoru, Yoshida Ryuichi, Tazawa Hiroshi, Kagawa Shunsuke, Yagi Takahito, Urata Yasuo, Fujiwara Toshiyoshi
机构信息
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Minimally Invasive Therapy Center, Okayama University Hospital, Okayama, Japan.
出版信息
Br J Cancer. 2024 Nov;131(10):1716-1717. doi: 10.1038/s41416-024-02850-0.
Abstract
摘要
相似文献
1
Author Correction: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.作者更正：表达p53的端粒酶特异性溶瘤腺病毒对胰腺癌抗肿瘤免疫的长期激活
Br J Cancer. 2024 Nov;131(10):1716-1717. doi: 10.1038/s41416-024-02850-0.
2
Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.携带 p53 基因的端粒酶靶向溶瘤腺病毒激活胰腺癌的长期抗肿瘤免疫。
Br J Cancer. 2024 Apr;130(7):1187-1195. doi: 10.1038/s41416-024-02583-0. Epub 2024 Feb 5.
3
Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity.树突状细胞成熟是由 p53 武装的溶瘤腺病毒通过肿瘤衍生的外泌体增强全身抗肿瘤免疫诱导的。
Cancer Immunol Immunother. 2024 Nov 5;74(1):12. doi: 10.1007/s00262-024-03849-5.
4
[Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer].[表达p53基因的端粒酶特异性溶瘤腺病毒刺激胰腺癌中的CD8 +记忆T细胞]
Gan To Kagaku Ryoho. 2022 Oct;49(10):1127-1129.
5
Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.溶瘤病毒介导的p53过表达促进胰腺癌中的免疫原性细胞死亡及PD-1阻断疗法的疗效。
Mol Ther Oncolytics. 2022 Sep 13;27:3-13. doi: 10.1016/j.omto.2022.09.003. eCollection 2022 Dec 15.
6
A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.缺氧和端粒酶反应性溶瘤腺病毒表达可分泌的三聚体 TRAIL 触发肿瘤特异性细胞凋亡，并促进 TRAIL 耐药性脑胶质瘤中的病毒扩散。
Sci Rep. 2018 Jan 23;8(1):1420. doi: 10.1038/s41598-018-19300-6.
7
A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.通过 E1A 依赖性 p21 和 MDM2 抑制实现基因工程腺病毒介导的肿瘤特异性 p53 过表达的新型凋亡机制。
Eur J Cancer. 2012 Sep;48(14):2282-91. doi: 10.1016/j.ejca.2011.12.020. Epub 2012 Jan 13.
8
[Anti-Tumor Effect of a Novel Oncolytic Virus Based on Chimpanzee Adenovirus Type 6].[基于黑猩猩6型腺病毒的新型溶瘤病毒的抗肿瘤作用]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Jan;53(1):71-76. doi: 10.12182/20220160504.
9
Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.DNA疫苗与表达GM-CSF和TGF-β2的短发夹RNA的溶瘤腺病毒联合进行的初免-加强免疫可诱导抗肿瘤免疫激活。
Oncotarget. 2017 Feb 28;8(9):15858-15877. doi: 10.18632/oncotarget.15008.
10
Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.骨肉瘤和软组织肉瘤：端粒酶特异性溶瘤病毒疗法的新靶点。
Cancers (Basel). 2020 Feb 18;12(2):478. doi: 10.3390/cancers12020478.
引用本文的文献
1
Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity.树突状细胞成熟是由 p53 武装的溶瘤腺病毒通过肿瘤衍生的外泌体增强全身抗肿瘤免疫诱导的。
Cancer Immunol Immunother. 2024 Nov 5;74(1):12. doi: 10.1007/s00262-024-03849-5.
Zotero 插件